一图速览 | 和铂医药2021年度社会责任报告

2022-05-05

关于和铂医药

和铂医药（股票代码：02142.HK）是一家专注于肿瘤及免疫性疾病领域创新药研发及商业化的全球化生物制药企业。公司通过自主研发、联合开发及多元化的合作模式快速拓展创新药研发管线。

和铂自有的抗体技术平台Harbour Mice®可生成双重、双轻链（H2L2）和仅重链（HCAb）形式的全人源单克隆抗体。基于HCAb抗体平台开发的免疫细胞衔接器（HBICE®）能够实现传统药物联合疗法无法达到的抗肿瘤疗效。Harbour Mice®与单克隆B细胞筛选平台共同组成了和铂的下一代创新治疗性抗体研发引擎。

更多信息，请访问：www.harbourbiomed.com

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":616645765,"tweetId":"616645765","gmtCreate":1651738500000,"gmtModify":1651755717096,"author":{"id":4089768869692920,"idStr":"4089768869692920","authorId":4089768869692920,"authorIdStr":"4089768869692920","name":"和铂医药","avatar":"https://static.tigerbbs.com/3d4aee977301cde1582403939a2d1fb8","vip":5,"userType":5,"introduction":"和创新药，铂铸健康","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":3628,"starInvestorFlag":false},"themes":[],"images":[{"img":"https://static.tigerbbs.com/c8a35d5ee527411eb98cde776aafc4d8"},{"img":"https://static.tigerbbs.com/c95920e4b2e0413aa60daec4d94bc4ee"},{"img":"https://static.tigerbbs.com/7ffdfe1d978b4b50be006aac46b79298"},{"img":"https://static.tigerbbs.com/320373dbf1814073953d9681fd2db7a4"},{"img":"https://static.tigerbbs.com/c3d496c1c9904e8aba148a75ecdb47c9"},{"img":"https://static.tigerbbs.com/62ff322ab9b84e45a39d74ea65a0ace1"},{"img":"https://static.tigerbbs.com/83dcad5f5f084987a59c7b46919db88d"},{"img":"https://static.tigerbbs.com/1bdf773e5d104f70b43e09cac1040e88"}],"coverImages":[{"img":"https://static.tigerbbs.com/c8a35d5ee527411eb98cde776aafc4d8"},{"img":"https://static.tigerbbs.com/c95920e4b2e0413aa60daec4d94bc4ee"},{"img":"https://static.tigerbbs.com/7ffdfe1d978b4b50be006aac46b79298"}],"title":"一图速览 | 和铂医药2021年度社会责任报告","extraTitle":"","html":"<html><head></head><body><img src=\"https://static.tigerbbs.com/c3d496c1c9904e8aba148a75ecdb47c9\"> <img src=\"https://static.tigerbbs.com/1bdf773e5d104f70b43e09cac1040e88\"> <img src=\"https://static.tigerbbs.com/7ffdfe1d978b4b50be006aac46b79298\"> <img src=\"https://static.tigerbbs.com/62ff322ab9b84e45a39d74ea65a0ace1\"> <img src=\"https://static.tigerbbs.com/83dcad5f5f084987a59c7b46919db88d\"> <img src=\"https://static.tigerbbs.com/c95920e4b2e0413aa60daec4d94bc4ee\"> <img src=\"https://static.tigerbbs.com/320373dbf1814073953d9681fd2db7a4\"> <img src=\"https://static.tigerbbs.com/c8a35d5ee527411eb98cde776aafc4d8\"> 关于和铂医药 和铂医药（股票代码：02142.HK）是一家专注于肿瘤及免疫性疾病领域创新药研发及商业化的全球化生物制药企业。公司通过自主研发、联合开发及多元化的合作模式快速拓展创新药研发管线。 和铂自有的抗体技术平台Harbour Mice®可生成双重、双轻链（H2L2）和仅重链（HCAb）形式的全人源单克隆抗体。基于HCAb抗体平台开发的免疫细胞衔接器（HBICE®）能够实现传统药物联合疗法无法达到的抗肿瘤疗效。Harbour Mice®与单克隆B细胞筛选平台共同组成了和铂的下一代创新治疗性抗体研发引擎。 更多信息，请访问：www.harbourbiomed.com </body></html>","htmlText":"<html><head></head><body><img src=\"https://static.tigerbbs.com/c3d496c1c9904e8aba148a75ecdb47c9\"> <img src=\"https://static.tigerbbs.com/1bdf773e5d104f70b43e09cac1040e88\"> <img src=\"https://static.tigerbbs.com/7ffdfe1d978b4b50be006aac46b79298\"> <img src=\"https://static.tigerbbs.com/62ff322ab9b84e45a39d74ea65a0ace1\"> <img src=\"https://static.tigerbbs.com/83dcad5f5f084987a59c7b46919db88d\"> <img src=\"https://static.tigerbbs.com/c95920e4b2e0413aa60daec4d94bc4ee\"> <img src=\"https://static.tigerbbs.com/320373dbf1814073953d9681fd2db7a4\"> <img src=\"https://static.tigerbbs.com/c8a35d5ee527411eb98cde776aafc4d8\"> 关于和铂医药 和铂医药（股票代码：02142.HK）是一家专注于肿瘤及免疫性疾病领域创新药研发及商业化的全球化生物制药企业。公司通过自主研发、联合开发及多元化的合作模式快速拓展创新药研发管线。 和铂自有的抗体技术平台Harbour Mice®可生成双重、双轻链（H2L2）和仅重链（HCAb）形式的全人源单克隆抗体。基于HCAb抗体平台开发的免疫细胞衔接器（HBICE®）能够实现传统药物联合疗法无法达到的抗肿瘤疗效。Harbour Mice®与单克隆B细胞筛选平台共同组成了和铂的下一代创新治疗性抗体研发引擎。 更多信息，请访问：www.harbourbiomed.com </body></html>","text":"关于和铂医药 和铂医药（股票代码：02142.HK）是一家专注于肿瘤及免疫性疾病领域创新药研发及商业化的全球化生物制药企业。公司通过自主研发、联合开发及多元化的合作模式快速拓展创新药研发管线。 和铂自有的抗体技术平台Harbour Mice®可生成双重、双轻链（H2L2）和仅重链（HCAb）形式的全人源单克隆抗体。基于HCAb抗体平台开发的免疫细胞衔接器（HBICE®）能够实现传统药物联合疗法无法达到的抗肿瘤疗效。Harbour Mice®与单克隆B细胞筛选平台共同组成了和铂的下一代创新治疗性抗体研发引擎。 更多信息，请访问：www.harbourbiomed.com","highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/616645765","repostId":0,"isVote":1,"tweetType":1,"viewCount":54401,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["02142"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":474,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/616645765"}